Literature DB >> 16816372

Role of neuronal interferon-gamma in the development of myelopathy in rats infected with human T-cell leukemia virus type 1.

Yukiko Miyatake1, Hitoshi Ikeda, Akihiro Ishizu, Tomohisa Baba, Toru Ichihashi, Akira Suzuki, Utano Tomaru, Masanori Kasahara, Takashi Yoshiki.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of not only adult T-cell leukemia but also HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Among the rat strains infected with HTLV-1, chronic progressive myelopathy, named HAM rat disease, occurs exclusively in WKAH rats. In the present study, we found that HTLV-1 infection induces interferon (IFN)-gamma production in the spinal cords of HAM-resistant strains but not in those of WKAH rats. Neurons were the major cells that produced IFN-gamma in HTLV-1-infected, HAM-resistant strains. Administration of IFN-gamma suppressed expression of pX, the gene critically involved in the onset of HAM rat disease, in an HTLV-1-immortalized rat T-cell line, indicating that IFN-gamma protects against the development of HAM rat disease. The inability of WKAH spinal cord neurons to produce IFN-gamma after infection appeared to stem from defects in signaling through the interleukin (IL)-12 receptor. Specifically, WKAH-derived spinal cord cells were unable to up-regulate the IL-12 receptor beta2 gene in response to IL-12 stimulation. We suggest that the failure of spinal cord neurons to produce IFN-gamma through the IL-12 pathway is involved in the development of HAM rat disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816372      PMCID: PMC1698768          DOI: 10.2353/ajpath.2006.051225

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  A novel polymorphic GATA site in the human IL-12Rbeta2 promoter region affects transcriptional activity.

Authors:  J G I van Rietschoten; R Westland; R van den Bogaard; M A Nieste-Otter; A van Veen; R E Jonkers; T C T M van der Pouw Kraan; M T den Hartog; E A Wierenga
Journal:  Tissue Antigens       Date:  2004-06

2.  T-lymphocyte alveolitis, tropical spastic paresis, and Sjögren syndrome.

Authors:  J C Vernant; G Buisson; J Magdeleine; J De Thore; A Jouannelle; C Neisson-Vernant; N Monplaisir
Journal:  Lancet       Date:  1988-01-23       Impact factor: 79.321

3.  T-lymphocyte alveolitis in HTLV-I-associated myelopathy.

Authors:  M Sugimoto; H Nakashima; S Watanabe; E Uyama; F Tanaka; M Ando; S Araki; S Kawasaki
Journal:  Lancet       Date:  1987-11-21       Impact factor: 79.321

4.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

5.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

6.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

7.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia.

Authors:  Jifen Li; Bruno Gran; Guang Xian Zhang; Elvira S Ventura; Ines Siglienti; Abdolmohamad Rostami; Malek Kamoun
Journal:  J Neurol Sci       Date:  2003-11-15       Impact factor: 3.181

9.  Exacerbations of multiple sclerosis in patients treated with gamma interferon.

Authors:  H S Panitch; R L Hirsch; A S Haley; K P Johnson
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  5 in total

1.  Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon.

Authors:  Shuichi Kinpara; Atsuhiko Hasegawa; Atae Utsunomiya; Hironori Nishitsuji; Hiroyuki Furukawa; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

Review 2.  Animal Models Utilized in HTLV-1 Research.

Authors:  Amanda R Panfil; Jacob J Al-Saleem; Patrick L Green
Journal:  Virology (Auckl)       Date:  2013-11-18

3.  The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases.

Authors:  Mari Kannagi; Atsuhiko Hasegawa; Ayako Takamori; Shuichi Kinpara; Atae Utsunomiya
Journal:  Front Microbiol       Date:  2012-09-03       Impact factor: 5.640

4.  Induction of Inflammation In Vivo by Electrocardiogram Sensor Operation Using Wireless Power Transmission.

Authors:  Jin-Chul Heo; Beomjoon Kim; Yoon-Nyun Kim; Dae-Kwang Kim; Jong-Ha Lee
Journal:  Sensors (Basel)       Date:  2017-12-14       Impact factor: 3.576

Review 5.  Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Retrovirology       Date:  2019-11-29       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.